46 AVENUE DE LA GRANDE ARMEE, PARIS, I0
MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Material disclosure
Subcutaneous Sarclisa Escena Approved in the US as First Anticancer Treatment Administered via On-Body Injector
Nexviazyme Met All Primary and Secondary Endpoints in Infantile-Onset Pompe Disease Phase 3 Study
Wayrilz approved in Japan to treat immune thrombocytopenia
Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Additional Information Statement
Contested Proxy Solicitation Materials
PRRN14A
Annual Report of Proxy Voting Record
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Quarterly Holdings Report for Institutional Managers
Amended Schedule 13G - Ownership Report
Annual Report of Employee Stock Purchase
NT 11-K
Specialized Disclosure Report
Iran Notice
Amended Tender Offer Statement by Third Party
S-8 POS